The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.

Benzer Materyaller

• Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease
  Yazar:: Piantoni, Silvia, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
  Yazar:: Scarsi, Mirko, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Reports of three long‐term lung disease following SARS‐CoV‐2 infection
  Yazar:: Piantoni, Silvia, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy
  Yazar:: Piantoni, Silvia, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
  Yazar:: Regola, Francesca, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)